Background and Aims: Lung cancer is the leading cause of cancer-related death in the world. Though many improvements in medical and surgical therapies have been done, the advancement in lung cancer mortality remains unsatisfactory. Targeting metabolic reprogramming in cancer has become an emerging strategy. For example, a widely used anti-diabetic drug, metformin, has been shown to have anti-cancer activities. However, the efficacy and safety of many of these metabolictargeting drugs are unexpectedly inadequate.
Methods: Here, we tried to stratify non-small cell lung cancer (NSCLC) cells by their glycolytic dependency and increase anti-cancer activities of these metabolic-targeting drugs according to their metabolic subtypes.
Results: We found that NSCLC cells could be classified into oxidative phosphorylation-dependent and glycolysis-dependent subtypes. The former is sensitive to metformin but the latter is resistant. To target these metformin-resistant cells, monocarboxylate transporter 4 (MCT4), a lactate transporter, was identified. It was found to be overexpressed and regulated by Sp1 and p63 transcription factors in the glycolysis-dependent subtype of NSCLC cells. Besides, the lactate-transporting function of MCT4 was shown to play an important role in cancer cell proliferation. When we knockdown the expression of MCT4 by using shRNAs, the proliferation of these cells would be inhibited.
Conclusion:
These results implied the potential of MCT4 as a druggable target against the glycolysis-dependent subtype of NSCLC. Here, a MCT4-neutralizing antibody has been developed with excellent antiproliferation activity in vitro and in vivo. We strongly believe that after a series of optimizations this MCT4-neutralizing antibody will have great potential to become a novel anti-cancer reagent against the glycolysisdependent subtype of NSCLC. axis. The new ACE2/Ang-(1-7)/Mas axis always plays a contrary role in many diseases. Ang-(1-7) reduced proliferation and angiogenesis in cancer. Our previous study found that Ang-(1-7) suppressed non-small cell lung cancer (NSCLC) migration and invasion. In this study, we investigated the effect of Ang-(1-7) on tumor-associated angiogenesis after the development of acquired platinum resistance in NSCLC.
Methods: qRT-PCR and western blot were carried out to detect the expression of ACE, AT1R, VEGFa, and signaling pathways productions. The proliferation-related gene Ki-67 and VEGFa was examined by immunohistochemistry. Microvessel density (MVD) were used to measure tumor-associated angiogenesis. Enzyme-linked immunosorbent assay (ELISA) were carried out to detect VEGFa expression levels.
Results: We found that ACE, AT1R and VEGFa productions decreased in the A549-DDP-Ang-(1-7) group than the A549-DDP group. The effects were blocked by the combination treatment of A779, the MAS receptor antagonist. The effect of Ang-(1-7) was partially mediated through inactivation of PI3K, P38 and ERK1/2 pathways. Additionally, we confirmed that Ang-(1-7) inhibited VEGFa production and microvessel density (MVD) development while simultaneously suppressed ACE and angiotensin II type 1 receptor (AT1R) expression in vivo.
Our results suggested Ang-(1-7) may potentially suppressed tumor associated angiogenesis induced by acquired platinum resistance in NSCLC. 
